Granza Bio

Granza Bio is an early-stage biotechnology company reprogramming immunity for target-specific medicines. Founded in 2024 by Dr. Ashwin Nandakumar, Dr. Ashwin Jainarayanan, and Prof. Michael Dustin, the company builds on the discovery of "attack particles" — killing entities released by cytotoxic immune cells, characterized in Prof. Dustin's laboratory at the University of Oxford. Granza Bio is developing an engineered delivery-shell platform that directs therapeutic cargo to specific tissues, with the goal of advancing treatments for cancers, autoimmune disorders, and infections. The company raised $7.14M in seed funding co-led by Refactor Capital and Felicis, with participation from Pioneer Fund and Y Combinator. It is a research-stage life-sciences company and does not currently publish a public developer API, SDK, or developer portal; this profile is maintained in the API Evangelist network as a company record.

Granza Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Immunotherapy, Drug Delivery, and Life Sciences.

Granza Bio’s developer surface includes engineering blog and 3 more developer resources.

🌐 Visit website 📡 Source on GitHub
6.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyBiotechnologyImmunotherapyDrug DeliveryLife SciencesOncologyTherapeutics

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 6.7/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.4 / 17
Access Clarity 1.8 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 1.9 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/granzabio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Granzabio Domain Security

TLSv1.3 · HSTS

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy

Company 2

The organization behind the API

Website
Website
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: granzabio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/granzabio.png
name: Granza Bio
description: Granza Bio is an early-stage biotechnology company reprogramming immunity for target-specific medicines. Founded
  in 2024 by Dr. Ashwin Nandakumar, Dr. Ashwin Jainarayanan, and Prof. Michael Dustin, the company builds on the discovery
  of "attack particles" — killing entities released by cytotoxic immune cells, characterized in Prof. Dustin's laboratory
  at the University of Oxford. Granza Bio is developing an engineered delivery-shell platform that directs therapeutic cargo
  to specific tissues, with the goal of advancing treatments for cancers, autoimmune disorders, and infections. The company
  raised $7.14M in seed funding co-led by Refactor Capital and Felicis, with participation from Pioneer Fund and Y Combinator.
  It is a research-stage life-sciences company and does not currently publish a public developer API, SDK, or developer portal;
  this profile is maintained in the API Evangelist network as a company record.
url: https://raw.githubusercontent.com/api-evangelist/granzabio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- felicis
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Immunotherapy
- Drug Delivery
- Life Sciences
- Oncology
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://granzabio.com
- type: Blog
  name: Newsroom
  url: https://www.granzabio.com/newsroom
- type: PrivacyPolicy
  url: https://www.granzabio.com/privacy-policy
- type: DomainSecurity
  url: security/granzabio-domain-security.yml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence